The global drug discovery service market size was valued at USD 15.41 billion in 2025 and is projected to grow from USD 17.57 billion in 2026 to USD 50.11 billion by 2034, registering a CAGR of 14% during the forecast period from 2026 to 2034. North America dominated the drug discovery service market with a market share of 41.5% in 2025.
Drug discovery services are specialized research and development solutions that support pharmaceutical and biotechnology companies in identifying and developing potential new medicines. These services cover activities such as target identification, screening, hit-to-lead development, lead optimization, and preclinical research. By providing scientific expertise, advanced technologies, and laboratory capabilities, drug discovery service providers help companies reduce development time, manage research costs, and improve the efficiency of early-stage drug development.
Download a Free Sample To learn more about this report,
Growing Adoption of Generative AI for Molecular Design
The drug discovery service market is increasingly incorporating generative AI into early-stage molecule design to evaluate chemical space faster than conventional screening alone. AI models can propose new molecular structures, predict useful properties, and prioritize candidates before expensive laboratory experiments begin. Contract research providers can combine these computational capabilities with medicinal chemistry and biological testing to shorten iterative discovery cycles for pharmaceutical clients. AI-assisted molecular design is therefore becoming an important part of drug discovery service market trends.
In January 2025, Charles River Laboratories entered a collaboration with Valence Labs to provide clients access to AI-enabled molecular design through its discovery services. The collaboration combines Charles River's experimental capabilities with generative AI models trained using more than 10 million compounds.
Increasing Use of Patient-Derived Organoids in Preclinical Discovery
Drug discovery providers are expanding the use of three-dimensional patient-derived organoids because conventional two-dimensional cell cultures may not adequately reproduce the biological complexity of human tissues. Organoids can preserve important cellular and disease characteristics, allowing researchers to evaluate candidate responses in models that more closely resemble human biology. This can improve compound selection before costly downstream development. Advanced human-relevant models are expanding the drug discovery service industry toward more predictive preclinical testing.
In June 2025, Crown Bioscience expanded its organoid discovery capabilities with a new high-throughput screening platform covering more than 200 patient-derived organoid models across multiple cancer indications, enabling larger-scale evaluation of oncology compounds in human-derived systems.
Increasing Pharmaceutical R&D Outsourcing
Drug developers are increasingly outsourcing discovery activities to specialist providers to access scientific expertise and laboratory infrastructure without building every capability internally. External partners can provide medicinal chemistry, screening, structural biology, pharmacology, and other services while allowing sponsors to adjust resources as individual programs progress. This flexibility is particularly valuable for biotechnology companies managing multiple pipelines with limited internal infrastructure. Greater outsourcing is therefore strengthening drug discovery service market demand.
In February 2026, WuXi AppTec reported that its continuing operations generated approximately RMB 45.5 billion in 2025 revenue, representing growth of more than 20%, while its backlog reached approximately RMB 60 billion, demonstrating strong demand for outsourced pharmaceutical research and development capabilities.
Biotechnology Funding Pressure Can Delay Early-Stage Research Programs
Emerging biotechnology companies represent important customers for discovery service providers, but their research spending depends heavily on access to venture capital and public financing. Difficult financing conditions can cause companies to reduce pipelines, postpone experiments, or concentrate resources on fewer lead programs. These decisions directly affect outsourced screening, chemistry, and biology workloads. Funding uncertainty can consequently restrain drug discovery service market growth even when long-term pharmaceutical innovation remains strong.
In March 2025, Evotec announced measures targeting more than EUR 300 million in annualized revenue growth alongside approximately EUR 40 million in additional annualized cost savings by the end of 2026, reflecting the operational pressure affecting discovery-service businesses amid tighter biotechnology spending.
Expansion of Radiopharmaceutical Drug Discovery
Radiopharmaceuticals are creating a distinct service opportunity because their development requires specialized expertise in isotope handling, radiochemistry, conjugation, analytical testing, and biological evaluation. Many pharmaceutical and biotechnology companies do not maintain these capabilities internally, increasing the value of external discovery partners with dedicated infrastructure. Growth in targeted radiotherapies and diagnostic agents can therefore help providers increase drug discovery service market share through specialized research services.
In May 2025, Symeres expanded into radiopharmaceutical discovery through a strategic collaboration with NRG. The partnership provides access to medical isotopes and specialized radiochemistry capabilities, supporting discovery programs involving multiple radionuclides for therapeutic development.
Improving Translation From Preclinical Models to Human Outcomes
A compound can demonstrate promising activity in laboratory assays and animal studies yet fail when tested in humans because preclinical models cannot completely reproduce human physiology, disease heterogeneity, metabolism, or toxicity. These translational failures consume substantial time and development capital after discovery work has already been completed. Service providers must therefore improve model selection and experimental design to generate evidence that better predicts clinical behavior. Improving preclinical-to-clinical translation remains a major challenge as drug discovery service market size expands.
In April 2025, the U.S. Food and Drug Administration announced a program to reduce reliance on animal testing for monoclonal antibodies and other drugs by encouraging AI-based computational models, organ-on-chip systems, and additional human-relevant methods, with implementation beginning immediately and a broader roadmap extending over 3–5 years.
Medicinal Chemistry Segment Dominated the Market with 28.4% Share in 2025
The medicinal chemistry segment dominated the global drug discovery service market with a 28.4% market share in 2025, valued at USD 4.38 billion. The segment's dominance is driven by its critical role in designing, synthesizing, and optimizing potential drug candidates. Increasing pharmaceutical R&D activities and growing outsourcing of specialized chemistry services continue to strengthen demand for medicinal chemistry capabilities.
The pharmacokinetics, drug metabolism, biology services, and other segments continue to witness strong demand as pharmaceutical and biotechnology companies require specialized expertise throughout drug discovery. Growing research complexity and the need to improve development efficiency are supporting these services.
Request Customizationto receive a tailored report.
The Hit-to-Lead Identification Segment is Projected to Register the Fastest Growth at a CAGR of 15.3%
The hit-to-lead identification segment is projected to register the fastest growth at a CAGR of 15.3% during the forecast period. Increasing use of high-throughput screening, computational approaches, and advanced analytical techniques to identify promising compounds is supporting segment expansion. Growing demand for faster and more efficient early-stage drug discovery is further strengthening adoption.
The target validation, target selection, candidate validation, lead optimization, and other processes remain essential throughout drug discovery. Increasing investment in pharmaceutical research and greater emphasis on selecting effective drug candidates are supporting demand across these stages.
Small Molecules Segment Dominated the Market with 56.3% Share in 2025
The small molecules segment dominated the global drug discovery service market with a 56.3% market share in 2025, valued at USD 8.68 billion. The segment's leadership is supported by established development processes, broad therapeutic applicability, and extensive pharmaceutical research focused on small-molecule drug candidates. Continued investment in novel therapies is strengthening demand for associated discovery services.
The biologics segment continues to experience strong growth as pharmaceutical and biotechnology companies expand research into antibodies, proteins, and other complex biological therapies. Advances in biotechnology and increasing development of targeted treatments are supporting demand for specialized biologics discovery services.
The oncology segment is Projected to Register the Fastest Growth at a CAGR of 16.1%
The oncology segment is projected to register the fastest growth at a CAGR of 16.1% during the forecast period. Increasing cancer research, growing development of targeted and personalized therapies, and strong pharmaceutical investment in novel oncology treatments are driving demand for specialized drug discovery services.
The neurology, diabetes, respiratory diseases, cardiovascular diseases, and other therapeutic areas continue to generate significant demand as companies pursue new treatments for chronic and complex diseases. Advances in disease biology and drug development technologies are expanding discovery activities across these therapeutic areas.
Pharmaceutical Companies Segment Dominated the Market with 46.8% Share in 2025
The pharmaceutical companies segment dominated the global drug discovery service market with a 46.8% market share in 2025, valued at USD 7.21 billion. The segment's dominance is driven by substantial R&D investment, extensive drug development pipelines, and increasing outsourcing of specialized discovery activities to improve efficiency, access advanced expertise, and optimize development resources.
The biotechnology companies, hospitals & clinics, and research institutes continue to utilize drug discovery services for early-stage research, therapeutic development, and scientific investigation. Growing collaborations and increasing access to specialized research capabilities are supporting adoption across these end-users.
Speak to an Analystto discuss market opportunities.
The North American drug discovery service market accounted for 41.5% of the global market, reaching USD 6.40 billion in 2025, and is projected to grow at a CAGR of 13.6% during the forecast period. Market growth is driven by strong pharmaceutical and biotechnology R&D activities, increasing outsourcing of drug discovery processes, growing adoption of AI-enabled discovery platforms, and rising investment in developing targeted therapies and novel drug candidates.
The United States represents the largest market in North America. Strong pharmaceutical and biotechnology industries, substantial investment in drug development, increasing outsourcing to specialized research organizations, and growing adoption of computational drug discovery, high-throughput screening, and advanced preclinical technologies continue to support market growth.
Expanding biotechnology research, increasing investment in life sciences, growing collaborations between academic institutions and pharmaceutical companies, and rising demand for specialized drug discovery and preclinical research services continue to support market development.
Unlock Regional Insightsto access country-level data, & regional trends.
The European drug discovery service market accounted for 27.4% of the global market, reaching USD 4.22 billion in 2025, and is expected to register a CAGR of 13.9% during the forecast period. Strong pharmaceutical research capabilities, expanding biotechnology ecosystems, increasing outsourcing of early-stage drug development, and growing investment in precision medicine and innovative therapeutics continue to support regional market expansion.
Germany represents a major European market. Strong pharmaceutical and biotechnology research capabilities, established academic research infrastructure, increasing demand for outsourced discovery services, and growing adoption of advanced screening and analytical technologies continue to support market growth.
The country's established life sciences ecosystem, strong academic research capabilities, expanding biotechnology sector, and increasing collaboration among pharmaceutical companies, research institutions, and specialized service providers continue to strengthen market development.
The Asia Pacific drug discovery service market accounted for 22.8% of the global market, reaching USD 3.51 billion in 2025, and is projected to register a CAGR of 16.8% during the forecast period. The region represents the fastest-growing market, supported by expanding pharmaceutical and biotechnology industries, increasing clinical and preclinical research activities, competitive research costs, improving scientific infrastructure, and growing outsourcing of drug discovery activities.
China represents a major market within the Asia Pacific. Rapid expansion of pharmaceutical and biotechnology R&D, increasing investment in innovative medicines, growing availability of specialized research organizations, and adoption of advanced screening and computational technologies continue to drive market expansion.
India's established pharmaceutical industry, expanding contract research capabilities, availability of skilled scientific professionals, competitive research costs, and increasing investment in biotechnology and innovative drug development continue to strengthen market growth.
Latin America's drug discovery service market accounted for 5.1% of the global market, reaching USD 0.79 billion in 2025, and is expected to grow at a CAGR of 12.7% during the forecast period. Expanding pharmaceutical research, improving clinical research infrastructure, growing international collaborations, and increasing outsourcing of research activities continue to support regional market development.
Brazil represents a major regional market. Expanding pharmaceutical and biotechnology research, increasing academic-industry collaboration, improving laboratory infrastructure, and growing participation in international drug development programs continue to create opportunities for drug discovery service providers.
The Middle East & Africa drug discovery service market accounted for 3.2% of the global market, reaching USD 0.49 billion in 2025, and is anticipated to grow at a CAGR of 11.9% during the forecast period. Increasing healthcare and life sciences investment, expanding research infrastructure, growing pharmaceutical manufacturing capabilities, and rising interest in biotechnology and precision medicine continue to support regional market development.
Increasing investment in biotechnology and pharmaceutical research, development of life sciences infrastructure, expanding academic research capabilities, and growing efforts to strengthen domestic drug development activities continue to support market growth.
Established biomedical research capabilities, expanding pharmaceutical research activities, growing academic and international collaborations, and increasing demand for specialized preclinical and drug discovery services continue to support steady market development.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
North America Clinical Trial Imaging Market Size, Share, and Forecast 2034
Europe Clinical Trial Imaging Market Analysis, Trends, Forecast Up to 2034
Asia Pacific Clinical Trial Imaging Market Size, Share and Forecast to 2034
India Pharmaceutical Stability and Storage Services Market Size, Share & Trends | Industry Report, 2034
Healthcare Regulatory Affairs Outsourcing Market Size, Share, 2034
Facial Fat Transfer Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com